Study on Long-Term Effects of B Cell Therapies for MS
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at how B cell therapies (a type of medicine for MS) create a long-lasting effect in people with relapsing-remitting multiple sclerosis. It aims to understand how these treatments work over time so doctors can better predict benefits and risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have relapsing-remitting multiple sclerosis (RRMS), a type of MS where symptoms come and go in attacks.
- You are currently taking a B cell therapy (medicines that affect certain immune cells) or are about to start or switch to one.
- You have a level of disability measured by the EDSS score between 0 and 7 (0 means no disability, 7 means you can walk with help but need a wheelchair for longer distances).
- You have never been treated with certain strong immune-suppressing drugs like alemtuzumab or cladribine, or had a bone marrow transplant.
- You do not have other conditions that would make it hard to understand the study, and you are not on long-term steroids or other immunosuppressants for non-MS reasons.
- You do not have HIV or Hepatitis C infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether treating relapsing multiple sclerosis (RRMS) aggressively and early with a specific medication can slow disease progression. You may qualify if you were recently diagnosed, have had recent disease activity, and are willing to take a strong immunosuppressive drug with regular MRI monitoring.
This Phase 3 study compares the best standard MS treatment (chosen by your doctors) versus an approach called autologous hematopoietic stem cell transplant (AHSCT) for people with highly active, treatment-resistant relapsing multiple sclerosis. It aims to see which option controls MS disease activity better and keeps you safer over time.
This trial tests a new treatment using your own immune cells trained with vitamin D to calm MS. It is for people with progressive MS who are not on other MS drugs.
This study looks at how well different treatments, including bone marrow transplant, alemtuzumab, ocrelizumab, and ofatumumab, work for people with relapsing-remitting MS who have active disease. It will help doctors understand which therapy might slow disease progression best.
This trial tests if it's safe to stop or reduce anti-CD20 treatment after several years of stable disease, compared to continuing it. It's for people with relapsing-remitting MS who are at least 40 years old and have had no MS activity for the past 3 years on anti-CD20 therapy.
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
Hear when a new Relapsing-remitting Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.